Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Cancer Res. 2021 Apr 5;81(8):2246–2255. doi: 10.1158/0008-5472.CAN-19-3093

Table 2.

Summary estimates for relative risks of site-specific cancers associated with the age at menarche, in multivariable models without, and with, additional adjustment for body mass index (BMI)

Model 1* Model 2† Percent difference in HR
HR Ptrend Phet HR Ptrend Phet
Endometrial cancer 0.91 (0.89-0.94) <.001 0.19 0.95 (0.92-0.98) <.001 0.16 4.0%
Liver cancer 0.92 (0.85-0.99) 0.02 0.39 0.94 (0.87-1.01) 0.07 0.40 2.3%
Melanoma 0.95 (0.93-0.98) <.001 0.21 0.95 (0.93-0.99) 0.002 0.25 0.0%
Bladder cancer 0.96 (0.93-0.99) 0.02 0.55 0.96 (0.93-1.00) 0.03 0.49 0.4%
Myeloid Leukemia 0.96 (0.91-1.02) 0.21 0.59 0.98 (0.93-1.04) 0.56 0.46 1.9%
Thyroid cancer 0.97 (0.92-1.01) 0.16 0.40 0.97 (0.93-1.02) 0.18 0.50 0.3%
Colon cancer 0.97 (0.96-0.99) <.001 0.88 0.98 (0.96-1.00) 0.04 0.76 0.6%
Lung cancer 0.98 (0.96-0.99) <.001 0.37 0.97 (0.95-0.99) <.001 0.37 −0.6%
Breast cancer 0.98 (0.97-0.98) <.001 0.94 0.98 (0.97-0.99) <.001 0.91 0.6%
Ovarian cancer 0.98 (0.95-1.01) 0.15 0.74 0.98 (0.95-1.01) 0.17 0.70 0.1%
Non-Hodgkin’s lymphoma 0.98 (0.96-1.01) 0.13 0.41 0.99 (0.96-1.01) 0.26 0.52 0.5%
Head & Neck 0.98 (0.94-1.03) 0.45 0.90 0.98 (0.94-1.02) 0.37 0.79 −0.3%
Kidney cancer 0.99 (0.95-1.03) 0.55 0.35 1.01 (0.97-1.06) 0.57 0.22 2.5%
Pancreatic cancer 0.99 (0.96-1.03) 0.62 0.63 1.00 (0.96-1.03) 0.83 0.56 0.5%
Lymphocytic Leukemia 0.99 (0.94-1.04) 0.76 0.61 0.99 (0.95-1.05) 0.84 0.53 0.3%
Rectal cancer 1.01 (0.97-1.04) 0.67 0.84 1.01 (0.98-1.05) 0.50 0.91 0.4%
Brain cancer 1.01 (0.96-1.06) 0.73 0.73 1.01 (0.96-1.06) 0.81 0.70 −0.3%
Gastric cancer, non-cardia 1.03 (0.96-1.11) 0.37 0.41 1.03 (0.96-1.11) 0.39 0.38 0.0%
Myeloma 1.03 (0.98-1.10) 0.25 0.27 1.04 (0.99-1.10) 0.17 0.26 0.6%
*

Model 1 included adjustments for baseline age, smoking, alcohol, race/ethnicity, education, and hormone replacement therapy, oral contraceptive use, age at menopause, parity and height.

†

Model 2 included adjustments for baseline age, smoking, alcohol, race/ethnicity, education, and hormone replacement therapy, oral contraceptive use, age at menopause, parity and height and BMI.